公开(公告)号：US12098144B2

公开(公告)日：2024-09-24

申请号：US18068902

申请日：2022-12-20

Applicant: Corcept Therapeutics Incorporated

Inventor： Mark Mills ,  Andrew William Phillips ,  Bohdan Waszkowycz ,  Hazel Joan Hunt ,  Angus Morrison ,  Angelo Pugliese ,  Jonathan Gillespie ,  Euan Fordyce

IPC: C07D403/14 ,  A61P43/00 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D403/14 ,  A61P43/00 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Provided are piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.

公开(公告)号：US20230192666A1

公开(公告)日：2023-06-22

申请号：US18068902

申请日：2022-12-20

Applicant: Corcept Therapeutics Incorporated

Inventor： Mark Mills ,  Andrew William Phillips ,  Bohdan Waszkowycz ,  Hazel Joan Hunt ,  Angus Morrison ,  Angelo Pugliese ,  Jonathan Gillespie ,  Euan Fordyce

IPC: C07D403/14 ,  C07D403/04 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14 ,  C07D413/14

CPC classification number: C07D403/14 ,  C07D403/04 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07B2200/09

Abstract: The present disclosure provides piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.